We will rely on you to help lend your voice and support the biotechnology industry.
Bringing new treatments to patients, support public policies that promote innovation, improve patient access.
BIO Latin America Conference
September 4-5, 2018
BIO Investor Forum
October 17-18, 2018
BIO Industry Analysis Reports >>
Save. Advocate. Connect. Join Us.
A listing of all BIO members and subsidiaries.
October 17 - 18, 2018 | San Francisco, California
Genine Winslow MSc. is founder and CEO of Chameleon Biosciences. Ms. Winslow founded Chameleon in 2017 to provide next-generation gene therapies to treat more patients with genetic diseases. Prior to Chameleon, Ms. Winslow was Director of Analytics at Audentes Therapeutics focusing on developing gene therapies for Myotubular Myopathy, Pompe Disease, and CASQ2-related Catecholaminergic Polymorphic ventricular tachycardia. At BioMarin, she was a Lead Scientist playing a key role in testing and process development for a Hemophilia A product. Before BioMarin, Ms. Winslow was instrumental in CMC development of Lentiviral-based gene therapies as a scientist at BlueBird Bio. Ms. Winslow began her career at Cell Genesys contributing to early CAR-T programs. All of the programs that Ms. Winslow was involved with are in clinical trials, 4 in pivotal clinical trials. Ms. Winslow has a B.Sc. in Genetics from UC Davis, and a M.Sc. in Molecular and Cell Biology, Immunology focus, from UC Berkeley.
This speaker's sessions: